News and Announcements
Motim Technologies Achieves Investment Target
- Published November 11, 2015 10:06AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Motim Technologies Limited has now achieved its investment target and is in over-subscription with its investment round scheduled to close at 10pm (NZT) on Wednesday 11 November 2015. Motim is a creative software technology company that works internationally with global brands, and is preparing to launch its new mobile SaaS platform early in 2016.
ABOUT MOTIM TECHNOLOGIES
Motim Technologies is a mobile software technology company that has been innovating in mobile marketing technology since 2007, providing creative technology for leading global brands and their advertising agencies that consumers choose to engage with, creating positive brand engagement that doesn’t feel like advertising.
To launch its SaaS platform in the USA and position the company for subsequent rapid expansion, Motim is seeking up to NZ$1,500,000 (24.1% of equity).
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
